跳至主要内容
临床试验/NCT01054131
NCT01054131已完成不适用

Peer to Peer Mentoring: Facilitating Individuals With Early Inflammatory Arthritis to Manage Their Arthritis: Peer Mentoring Program

Sunnybrook Health Sciences Centre1 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2010年1月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
10
试验地点
1
主要终点
DMARD adherence

研究概览

简要总结

Inflammatory arthritis (IA) is a major cause of long-term disability. Peer support may be a solution to the common problem of delayed treatment. Early peer support may result in improved use of therapy, higher self-efficacy, reduced anxiety, and improved coping in the first two years post-diagnosis. The whole intervention study comprises of two parts: The first part involves the development and testing of a peer mentor training initiative, which is called "Peer to Peer Mentoring: Facilitating Individuals with Early Inflammatory Arthritis to Manage their Arthritis - Peer Mentor Training". The second part, which is the focus of this study, involves the delivery of a one-on-one peer support intervention from a trained peer mentor to an individual newly diagnosed with EIA. The feasibility and acceptability of the program will be determined, as well as the health outcomes following the participation of the program.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Supportive Care

入排标准

性别
All
接受健康志愿者

入选标准

  • Have EIA disease duration within 6-52 weeks
  • At least 3 swollen joints, assessed by the treating rheumatologist, OR positive compression test for the metacarpophalangeal joints OR positive compression test for the metatarsophalangeal joints OR at least 30 minutes of morning stiffness
  • Prescription of a DMARD/biologic by the treating rheumatologist
  • Ability to speak and understand English without the aid of a secondary support person; AND
  • Capability to provide informed consent.

排除标准

  • IA disease duration less than 6 weeks or greater than 1 year
  • Previous or ongoing DMARD or biologic treatment
  • Inability to speak or read grade 6 English; AND
  • Inability to provide informed consent

结局指标

主要结局

DMARD adherence

时间窗: 0, 3, 6 months

次要结局

  • coping efficacy(0, 3 6 months)
  • self-management(0, 3, 6 months)
  • anxiety(0, 3, 6 months)
  • self efficacy(0, 3, 6 months)
  • social support(0, 3, 6 months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Dr. Mary Bell

Rheumatologist

Sunnybrook Health Sciences Centre

研究点 (1)

Loading locations...

相似试验